FDA Approves Six-Month Primary End Point for the Lutonix Below-the-Knee Drug Coated Balloon

News The clinical trial is evaluating the device when used for the treatment of stenosis or occlusion of native below-the-knee arteries with a cumulative lesion length up to 320 mm with reference vessel diameters of 2 to 4 mm. Contributed Author:  C. R. Bard, Inc. Topics:  Cardiovascular